Omnix Medical
Founded in 2015, Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing novel antibiotic agents to combat infections caused by drug-resistant bacteria. Their innovative technology focuses on natural antimicrobial peptides, engineered for therapeutic use, targeting severe hospital-acquired infections and addressing the urgent threat posed by multidrug-resistant pathogens. The company is building a pipeline of first-in-class anti-infectives designed to treat severe, potentially lethal infections associated with multi-drug resistances.
Omnix Medical
High-Tech Village Givat Ram Campus, Jerusalem Israel
What We Do
Antimicrobial Peptides Development
Development of novel antimicrobial peptides designed to effectively target and kill drug-resistant bacteria, particularly those causing hospital-acquired infections.
Regulatory Support
Assistance in navigating the regulatory pathways for drug approval, including obtaining Qualified Infectious Disease Product (QIDP) designation from the FDA.
A first-in-class drug targeting multidrug-resistant bacteria, utilizing a unique mechanism of action that avoids resistance development. OMN6 is currently being evaluated in a Phase-I trial in The Netherlands, targeting Gram-negative bacteria, particularly Acinetobacter baumannii.
OMN-51
A new antimicrobial peptide (AMP) targeting Gram-negative bacteria like P. aeruginosa, which causes recurrent infections in patients with Cystic Fibrosis.
OMN-71
A new antimicrobial peptide (AMP) targeting gastrointestinal tract infections involving Salmonella and bacteria involved in skin infections, particularly those resistant to current treatments.
Routes of Administration
Key People
News & Updates
Results from the first-in-human study of OMN6, a novel antimicrobial peptide for Acinetobacter baumannii, conducted in healthy volunteers.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA granted fast-track designation for OMN6, highlighting the urgent need for novel antimicrobials against Gram-negative bacteria.
Announcement of FDA approval for a Phase II trial of OMN6, aimed at treating life-threatening infections caused by Acinetobacter baumannii.
An overview of the innovative technology behind Omnix Medical's antibiotic development, focusing on antimicrobial peptides.
The Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of multidrug-resistant bacteria.